Antiretroviral therapy: dolutegravir sets SAIL(ING)

被引：4
|
作者：
Boyd, Mark A. [1 ]
Donovan, Basil [1 ]
机构：
[1] Univ New S Wales, Kirby Inst Infect & Immun Soc, Sydney, NSW 2052, Australia
来源：
LANCET | 2013年 / 382卷 / 9893期
关键词：
CO-FORMULATED ELVITEGRAVIR; HIV-1; INFECTION; DOUBLE-BLIND; INITIAL TREATMENT; CONTROLLED-TRIAL; RALTEGRAVIR; EMTRICITABINE; COBICISTAT; TENOFOVIR; EFAVIRENZ;
D O I：
10.1016/S0140-6736(13)61456-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：664 / 666
页数：3
相关论文
共 50 条
  • [21] Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients
    Nasreddine, Rakan
    Florence, Eric
    Vandercam, Bernard
    Moutschen, Michel
    Goffard, Jean-Christophe
    de Munter, Paul
    Delforge, Marc
    Marinus, Wouter
    De Wit, Stephane
    AIDS, 2020, 34 (08) : 1151 - 1159
  • [22] ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects
    Letendre, Scott L.
    Mills, Anthony M.
    Tashima, Karen T.
    Thomas, Deborah A.
    Min, Sherene S.
    Chen, Shuguang
    Song, Ivy H.
    Piscitelli, Stephen C.
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (07) : 1032 - 1037
  • [23] Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy
    Griesel, Rulan
    Kawuma, Aida N.
    Wasmann, Roeland
    Sokhela, Simiso
    Akpomiemie, Godspower
    Venter, W. D. Francois
    Wiesner, Lubbe
    Denti, Paolo
    Sinxadi, Phumla
    Maartens, Gary
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (03) : 883 - 893
  • [24] Immunological Efficacy and the Impact on Weight of Dolutegravir-Based Regimen in Antiretroviral Therapy (ART)-Naïve Patients with HIV Infection
    Zhong, Mingli
    Zhang, Xiang
    Guan, Hongjing
    Chen, Chen
    Cai, Rentian
    Qi, Mingxue
    Su, Yifan
    Yang, Yingying
    Xu, Xinglian
    Cheng, Cong
    Wei, Hongxia
    INFECTION AND DRUG RESISTANCE, 2024, 17 : 4921 - 4933
  • [25] Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject
    Rossotti, Roberto
    Maggioni, Marco
    Merli, Marco
    Orcese, Carloandrea
    Iavarone, Massimo
    Puoti, Massimo
    AIDS, 2018, 32 (12) : 1727 - 1729
  • [26] Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho
    Brown, Jennifer A.
    Nsakala, Bienvenu L.
    Mokhele, Kuena
    Rakuoane, Itumeleng
    Muhairwe, Josephine
    Glass, Tracy R.
    Amstutz, Alain
    Tschumi, Nadine
    Belus, Jennifer M.
    Klimkait, Thomas
    Labhardt, Niklaus D.
    HIV MEDICINE, 2023, 24 (02) : 153 - 162
  • [27] Prescribing for patients taking antiretroviral therapy
    Hughes, Yasmin
    Tomlins, Louise
    Usherwood, Tim
    AUSTRALIAN PRESCRIBER, 2022, 45 (03) : 80 - 87
  • [28] Update and latest advances in antiretroviral therapy
    Menendez-Arias, Luis
    Delgado, Rafael
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (01) : 16 - 29
  • [29] Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir
    Fulcher, Jennifer A.
    Du, Yushen
    Zhang, Tian-Hao
    Sun, Ren
    Landovitz, Raphael J.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (05) : 791 - 794
  • [30] Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    Clotet, Bonaventura
    Feinberg, Judith
    van Lunzen, Jan
    Khuong-Josses, Marie-Aude
    Antinori, Andrea
    Dumitru, Irina
    Pokrovskiy, Vadim
    Fehr, Jan
    Ortiz, Roberto
    Saag, Michael
    Harris, Julia
    Brennan, Clare
    Fujiwara, Tamio
    Min, Sherene
    LANCET, 2014, 383 (9936) : 2222 - 2231
12345